Efflux inhibition with verapamil potentiates bedaquiline in mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 574-576

  Gupta, Shashank ^a,b   Cohen, Keira A ^c,d   Winglee, Kathryn ^a   Maiga, Mamoudou ^a,e   Diarra, Bassirou ^e   Bishai, William R ^a,b,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^e UNIVERSITY OF BAMAKO   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; VERAPAMIL;

ADULT; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG INHIBITION; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERAPAMIL;

EID: 84891543452     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01462-13     Document Type: Article

References (19)

1. World Health Organization. 2013. Multidrug-resistant tuberculosis (MDRTB) 2013 update. World Health Organization, Geneva, Switzerland.
2. da Silva PE, Von Groll A, Martin A, Palomino JC. 2011. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 63:1-9. http://dx.doi.org/10.1111/j.1574-695X.2011.00831.x
3. Rodrigues L, Machado D, Couto I, Amaral L, Viveiros M. 2012. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 12:695-700. http://dx.doi.org/10.1016/j.meegid. 2011.08.009
4. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022
5. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 7:e34538. http://dx.doi.org/10.1371/journal.pone.0034538
6. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. 2013. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med. 188:600-607. http://dx.doi.org/10.1164/rccm.201304-0650OC
7. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276. http://dx.doi.org/10.1164/rccm.201011-1924OC
8. U.S. Food and Drug Administration 2013. FDA news release. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm. Accessed 2 July 2013
9. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753
10. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:2831-2835. http://dx.doi.org/10.1128/AAC.01204-07
11. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrugresistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56:3271-3276. http://dx.doi.org/10.1128/AAC.06126-11.
12. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427
13. World Health Organization. 2013. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. World Health Organization, Geneva, Switzerland.
14. Collins L, Franzblau SG. 1997. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41:1004-1009
15. Traore B, Diarra B, Dembele BP, Somboro AM, Hammond AS, Siddiqui S, Maiga M, Kone B, Sarro YS, Washington J, Parta M, Coulibaly N, M'Baye O, Diallo S, Koita O, Tounkara A, Polis MA. 2012. Molecular strain typing of Mycobacterium tuberculosis complex in Bamako, Mali. Int. J. Tuberc. Lung Dis. 16:911-916. http://dx.doi.org/10.5588/ijtld.11.0397
16. Maiga M, Siddiqui S, Diallo S, Diarra B, Traore B, Shea YR, Zelazny AM, Dembele BP, Goita D, Kassambara H, Hammond AS, Polis MA, Tounkara A. 2012. Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis. PLoS One 7:e36902. http://dx.doi.org/10.1371/ journal.pone.0036902
17. Neal RA, van Bueren J, McCoy NG, Iwobi M. 1989. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans. R. Soc. Trop. Med. Hyg. 83:197-198. http://dx.doi.org/10.1016/0035-9203(89)90642-1
18. Martin SK, Oduola AM, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901. http://dx.doi.org/10.1126/science.3544220
19. Johnston A, Burgess CD, Hamer J. 1981. Systemic availability of oralverapamil and effect on PR interval in man. Br. J. Clin. Pharmacol. 12:397-400. http://dx.doi.org/10.1111/j.1365-2125.1981.tb01233.x.